A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report.

ABSTRACT:

Background

Inflammatory myofibroblastic tumor (IMT) is a rare disease that mainly involves the lung and the abdomen. The gold standard of the IMT treatment is radical surgery, while chemotherapy and radiotherapy are represented usually for unresectable lesions. Anaplastic lymphoma kinase (ALK) rearrangements are present in approximately 50% of IMT patients, and several clinical trials of ALK tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive IMT patients are underway.

Case description

We reported a case of IMT in the right pelvic cavity. Initially, the patient underwent resection of multiple lesions. Unfortunately, the patient's tumor recurred half a year later, and enhanced computerized tomography (CT) of the whole abdomen revealed multi

SUBMITTER: Xu X 

PROVIDER: S-EPMC9552075 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature